Santen Pharmaceutical Co., Ltd.
Records under this name other than the patents Santen Pharmaceutical Co., Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 70 patents it holds.
Back to Santen Pharmaceutical Co., Ltd.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,008,496 | 1,2-dihydroquinoline derivative having substituted phenylchalcogeno lower alkyl group and ester-introduced phenyl group as substituents Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,901,155 | Method for treating a TRPV1-mediated disease Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,017,775 | 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity Formerly held In force · USPTO record | In force | USPTO record | |
| US 9,999,593 | Method and Composition for Treating Ocular Hypertension and Glaucoma Formerly held In force · High confidence | In force | High confidence | |
| US 8,426,406 | Glucocorticoid receptor agonist comprising 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivatives having substituted oxy group Formerly held In force · USPTO record | In force | USPTO record | |
| US 11,707,577 | Accurate, Precise Microliter Dosing Syringe Formerly held In force · High confidence | In force | High confidence | |
| US 11,331,322 | Medicament for Preventing And/Or Treating Dry Eye Formerly held In force · High confidence | In force | High confidence | |
| US 12,005,063 | Medicament for Preventing And/Or Treating Dry Eye Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 11,439,652 | Ophthalmic Aqueous Composition Formerly held Lapsed on the fee record Ended Sep 13, 2026 · High confidence | Lapsed on the fee record | Ended Sep 13, 2026 | High confidence |
| US 10,071,113 | Ophthalmic Solution Comprising Diquafosol Lapsed on the fee record Ended Sep 11, 2026 · High confidence | Lapsed on the fee record | Ended Sep 11, 2026 | High confidence |